Taiyen Biotech Co. Ltd. said its first-quarter normalized net income amounted to 19 Taiwan cents per share, an increase from 18 cents per share in the prior-year period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was NT$37.5 million, a gain from NT$36.7 million in the prior-year period.
The normalized profit margin increased to 5.9% from 5.8% in the year-earlier period.
Total revenue grew on an annual basis to NT$639.3 million from NT$628.6 million, and total operating expenses declined on an annual basis to NT$561.1 million from NT$586.8 million.
Reported net income fell 36.5% from the prior-year period to NT$48.3 million, or 24 cents per share, from NT$76.0 million, or 38 cents per share.
As of April 15, US$1 was equivalent to NT$31.25.
